Ameliorating effect of coenzyme Q10, riboflavin and niacin in tamoxifen-treated postmenopausal breast cancer patients with special reference to lipids and lipoproteins

Clinical Biochemistry

Volumn 40, Issue 9-10, 2007, Pages 623-628

  Yuvaraj, Srinivasan ^a   Premkumar, Vummidi Giridhar ^a   Vijayasarathy, Kothandaraman ^b   Gangadaran, Sitthu Govindaswamy Dinakaran ^b   Sachdanandam, Panchanatham ^a  

^a UNIVERSITY OF MADRAS   (India)

^b Kilpauk Medical College   (India)

Author keywords

Breast cancer; Coenzyme Q10; Lipid; Lipoproteins; Niacin; Riboflavin; Tamoxifen

Indexed keywords

FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PHOSPHOLIPID; RIBOFLAVIN; TAMOXIFEN; TRIACYLGLYCEROL; UBIDECARENONE; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFECT; FATTY ACID BLOOD LEVEL; FEMALE; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; PHOSPHOLIPID BLOOD LEVEL; POSTMENOPAUSE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

ADULT; AGED; BREAST NEOPLASMS; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; COENZYMES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERLIPIDEMIAS; LIPID METABOLISM; LIPOPROTEINS; MIDDLE AGED; NIACIN; POSTMENOPAUSE; RIBOFLAVIN; TAMOXIFEN; TRIGLYCERIDES; UBIQUINONE;

EID: 34249688738     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2007.02.003     Document Type: Article

References (45)

1. McPherson K., Steel C.M., and Dixon J.M. ABC of the breast diseases, breast cancer epidemiology, risk factors and genetics. BMJ 321 (2000) 624-628
2. Clemons M., Danson S., and Howell A. Tamoxifen ('Nolvadex'); a review. Cancer Treat Rev. 28 (2002) 165-180
3. Rutqvist L.E., Johansson H., Signomklao T., Johansson U., Fornande T., and Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J. Natl. Cancer Inst. 87 (1995) 645-651
4. Narod S.A., Brunet J.-S., Ghadirian P., et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet 356 (2001) 1876-1881
5. Fossati R., Confalonieri C., Torri V., et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J. Clin. Oncol. 16 (1998) 3439-3460
6. Howell A., Osborne C.K., Morris C., and Wakeling A.E. ICI 182,780 (Faslodex™). Development of novel, "pure" antiestrogen. Cancer 89 (2000) 817-825
7. Thangaraju M., Kumar K., Gandhirajan R., and Sachdanandam P. Effect of tamoxifen on plasma lipids and lipoproteins in post-menopausal women with breast cancer. Cancer 73 (1994) 653-663
8. Liu C.L., and Yang T.L. Sequential changes in serum triglycerides levels during adjuvant tamoxifen therapy in breast cancer patients and the effect of dose reduction. Breast Cancer Res. Treat 79 (2003) 11-16
9. Austin M.A., Hokanson J.E., and Edwards K.L. Hypertriglyceridemia as a cardiovascular risk factor. Am. J. Cardiol. 81 (1998) 7B-12B
10. Nohl H., Gille L., and Kozlou A.V. Critical aspects of the antioxidant function of coenzyme Q in biomembranes. BioFactors 9 (1999) 155-161
11. 10 concentration in coronary artery disease. Clin. Biochem. 37 (2004) 706-709
12. 10) in pediatric cardiomyopathy. Clin. Nutr. 24 (2005) 331-338
13. 10 : effects on lipidperoxidation and antioxidants in mitochondria. Chem.-Biol. Interact. 152 (2005) 49-58
14. Imada Y., Iida H., Ono S., and Murahashi S. Flavin catalyzed oxidation of sulfides and amines with molecular oxygen. J. Am. Chem. Soc. 125 (2003) 2868-2869
15. Ganji S.H., Kamanna V.S., and Kashyap M.L. Niacin and cholesterol: role in cardiovascular disease (Review). J. Nutr. Biochem. 14 (2003) 298-305
16. Leffer H.H., and McDougald C.H. Colorimetric method for the estimation of cholesterol. Am. J. Clin. Pathol. 39 (1963) 311-313
17. Horn W.T., and Menahan L.A. A sensitive method for the determination of free fatty acids in plasma. J. Lipid Res. 22 (1981) 377-381
18. Rouser G., Fleisher S., and Yamanoro A. Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spits. Lipids 5 (1970) 494-496
19. Friedald W.T., Levy R.I., and Fredriekson D.S. Estimation of concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin. Chem. 18 (1976) 499-502
20. ATAC Trialists Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 359 (2002) 2131-2139
21. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-I. J. Natl. Cancer Inst. 90 (1998) 1371-1388
22. IBIS Investigators Writing Committee. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomized prevention trial. Lancet 360 (2002) 817-824
23. Veronesi U., Maisonneuve P., Sacchini V., et al. Tamoxifen for breast cancer among hysterectomised women. Lancet 359 (2002) 1122-1124
24. Powles T., Eeles R., Ashley S., et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet 352 (1998) 98-101
25. Cuzick J., Powles T., Veronesi U., et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 361 (2003) 296-300
26. Stolar M.W. Atherosclerosis in diabetes: a role of hyperinsulinemia. Metab. Clin. Exp. 37 (1988) 1
27. Carloson L.A., and Bottiger L.E. Ischemic heart disease in relation to fasting values of plasma TG and cholesterol. Cancer 1 (1972) 865-868
28. Kumar K., Arivazhagan R., and Sachdanandam P. Studies on the changes in the plasma lipids and lipoprotein in patients with benign and malignant breast cancer. Biochem. Int. 23 (1991) 581-589
29. Summerfield F.W., and Tappel A.L. Determination of fluorescence quenching of the environment of DNA cross-links made by malondialdehyde. Biochem. Biophys. Acta 740 (1983) 276-282
30. Stepsenwol J. Carcinogenic effect of cholesterol in mice. Proc. Soc. Exp. Biol. Med. 121 (1966) 168-171
31. Holleran A.L., Lindenthal B., Aldaghlas T.A., and Kelleher J.K. Efect of tamoxifen on cholesterol synthesis in HepG2 cells and cultured rat hepatocytes. Metabolism 47 (1998) 1504-1513
32. Callaghan R., and Higgins C.F. Interaction of tamoxifen with multidrug resistance P-glycoprotein. Br. J. Cancer 71 (1995) 294-299
33. Assmann G., Schulte H., Funke H., and Von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur. Heart J. 19 Suppl. M (1998) M8-M14
34. James A.M., Robin Smith A.J., and Murphy P.M. Antioxidant and prooxidant properties of mitochondrial coenzyme Q. Arch. Biochem. Biophys. 423 (2004) 47-56
35. Kagan V., Serbinov E., and Packer L. Antioxidant effects of ubiquiones in microsomes and mitochondria are mediated by tocopherol recycling. Biochem. Biophys. Res. Commun. 169 3 (1990) 851-857
36. Watts G.F., Playford D.A., Croft D.K., et al. Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus. Diabetologia 45 (2002) 420-426
37. Maulik N., Yoshida T., Engelman R.M., et al. Dietary coenzyme Q(10) supplement renders swine hearts resistant to ischemia-reperfusion injury. Am. J. Physiol.: Heart Circ. Physiol. 278 (2000) 1084-1090
38. Rivlin R.S., and Riboflavin. In: Browman B.A., and Russell R.M. (Eds). Present knowledge in nutrition (2001), ILSI Press, Washington, DC 191-198
39. Wu G., Fang Y.Z., Yang S., Lupton J.R., and Turner N.D. Glutathione metabolism and its implications for health. J. Nutr. 134 (2004) 489-492
40. Clarke R., Daly L., Robinson K., et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N. Engl. J. Med. 324 (1991) 1149-1155
41. Hustad S., et al. Riboflavin as determinant of plasma total homocysteine: effect modification by the methylenetetrahydrofolate reductase C677T polymorphism. Clin. Chem. 46 8 Part 1 (2000) 1065-1071
42. Kashyap M.L. Mechanistic studies of high density lipoprotein. Am. J. Cardiol. 82 (1998) 42U-48U
43. Carlson L.A., Oro L., and Ostman J. Effect of single dose of nicotinic acid on plasma lipids in patients with hyperlipoproteinemia. Acta Med. Scand. 183 (1968) 457-465
44. Jin F.Y., Kamanna V.S., and Kashyap M.L. Niacin decreases removal of high density lipoprotein A-I but not cholesterol ester by Hep G2 cells. Implications for reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 2020-2028
45. Jin F.Y., Kamanna V.S., and Kashyap M.L. Niacin accelerates intracellular apo B degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (Hep G2) cells. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 1051-1059